drugset
Drugs / TH-1 Dendritic Cell Immunotherapy
last change Dec 2023 re-read 3 minutes ago

TH-1 Dendritic Cell Immunotherapy

Vaccine

Developed for
glioblastoma
Investigated by
Baylor College of Medicine · Philadelphia College of Osteopathic Medicine · The Cooper Health System

Trials 1

today NCT04552886 · Ph 1
20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04552886 Oct 2021 → Dec 2023 glioblastoma The Cooper Health System Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as TH-1 Dendritic Cell Immunotherapy ClinicalTrials.gov intervention name — accepted as the source's own label NCT04552886 ↗
Modality Vaccine “novel, personalized dendritic cell vaccine” NCT04552886 ↗